LOS ANGELES, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming November 10, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH) securities between February 26, 2025 and August 5, 2025, inclusive (the “Class Period”). IF YOU SUFFERED A LOSS ON YOUR LANTHEUS INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUIN ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Lantheus To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Lantheus between February 26, 2025 and August 5, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Far ...

Accessibility StatementSkip Navigation SAN DIEGO, Sept. 24, 2025 /PRNewswire/ -- Robbins LLPÂ reminds stockholders that a class action was filed on behalf of persons and entities that purchased or otherwise acquired Lantheus Holdings, Inc. (NASAQ: LNTH) securities between February 26, 2025 and August 5, 2025. Lantheus is a global company that develops, manufactures, sells, and distributes certain diagnostic and therapeutic products. The Company's key Radiopharmaceutical Oncology product is Pylarify, a PET i ...

NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Lantheus Holdings, Inc. (NASDAQ: LNTH) between February 26, 2025 and August 5, 2025, both dates inclusive (the “Class Period”), of the important November 10, 2025 lead plaintiff deadline. SO WHAT: If you purchased Lantheus securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arr ...

NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. The class action concerns whether Lantheus and certain ...

James (Josh) Wilson, Faruqi & Faruqi Senior Partner (PRNewsfoto/Faruqi & Faruqi, LLP) Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com. According to the complaint, defendants provided investors with misleading statements concerning the true state of Pylarify's competitive position; notably, that Lantheus was not equipp ...

SAN DIEGO, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Lantheus Holdings, Inc. (NASDAQ: LNTH) securities between February 26, 2025 and August 5, 2025, inclusive (the “Class Period”), have until Monday, November 10, 2025 to seek appointment as lead plaintiff of the Lantheus class action lawsuit. Captioned Margolis v. Lantheus Holdings, Inc., No. 25-cv-07491 (S.D.N.Y.), the Lantheus class action lawsuit charges Lantheus and certain of Lantheus’ ...

Core Insights - Lantheus Holdings and GE HealthCare have entered into an exclusive licensing agreement for the development, manufacturing, and commercialization of piflufolastat F18 (PYLARIFY) in Japan for prostate cancer diagnostics [1][2] - The partnership aims to enhance the reach of PYLARIFY in international markets, particularly in Japan, which has the third highest number of prostate cancer cases globally [3][4] - GE HealthCare will leverage its manufacturing network and R&D expertise, especially following its acquisition of Nihon Medi-Physics Co., Ltd. in March 2025 [2][3] Company Overview - Lantheus is a leading radiopharmaceutical-focused company, providing solutions for nearly 70 years, with a mission to improve patient outcomes through innovative diagnostics [19] - GE HealthCare is a global healthcare solutions provider with a focus on medical technology and pharmaceutical diagnostics, serving patients and providers for over 125 years [20] Product Information - PYLARIFY is a PSMA-targeted PET imaging agent approved by the FDA in 2021, and it has been utilized in over 500,000 scans across the U.S. [4] - The product is designed to visualize lymph nodes, bone, and soft tissue metastases in men with prostate cancer, combining the accuracy of PET imaging with the precision of PSMA targeting [5] Financial Terms - Under the agreement, GE HealthCare will pay Lantheus an upfront license fee, development milestones, and tiered royalties based on product sales in Japan [2][3]

Accessibility StatementSkip Navigation BENSALEM, Pa., Sept. 23, 2025 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ:Â LNTH). IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN LANTHEUS HOLDINGS, INC. (LNTH), CONTACT THE LAW OFFICES OF HOWARD G. SMITHÂ BEFORE NOVEMBER 10, 2025 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ON ...

LOS ANGELES--(BUSINESS WIRE)--Lantheus Holdings, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – LNTH. ...